Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
IPO Year: 2015
Exchange: NASDAQ
Website: bellerophon.com
| Date | Price Target | Rating | Analyst |
|---|
Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INO
WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has completed blinded treatment in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD). The Company expects to report top-line results from this study in mid-2023. "The successful and timely completion of the blinded treatment phase of our pivotal Phase 3 REBUILD trial represents a key milestone in our INOpulse® de
Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater ChinaStrengthened Balance Sheet Through $5 Million Registered Direct Offering with Life Sciences-focused Institutional Investor WARREN, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2022. "We have achieved significant recent pro
WARREN, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a subscription agreement with a life sciences-focused institutional investor to sell, in a registered direct offering, 718,474 shares of common stock at a price of $2.00 per share and 1,781,526 prefunded warrants at a price of $1.99 per pre-funded warrant for total gross proceeds of approximately $5 million, before deducting estimated offering expenses. The offering is expected to close on March 7, 2023, subject to the sa
WARREN, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced clearance of its Investigational New Drug (IND) application from the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) to conduct a Phase 3 clinical trial to support the registration of INOpulse® for the treatment of fibrotic interstitial lung disease (fILD) in China. The study will utilize Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint and be conducted in collaboration with Bellerophon's
WARREN, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has been enrolled in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD). The Company now expects to report pivotal top-line results in mid- 2023. "We are pleased to have completed enrollment in this important study sooner than previously anticipated, which represents a significant milestone for Bellerophon, our
WARREN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a license agreement for the development and commercialization of INOpulse® with Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China. Under the terms of the license agreement, Bellerophon will receive a license payment of $6 million, payable within 90 days subject to certain closing conditions set forth in the agreement. Additionall
WARREN, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2022. "We continue to achieve important progress in advancing the ongoing REBUILD Phase 3 trial of INOpulse® for the treatment of fibrotic Interstitial Lung Disease (fILD)," said Naseem Amin, M.D., Chairman of Bellerophon's Board of Directors. "With the recent U.S. Food and Drug Administration (FDA) acceptance of the reduction in the study sample si
New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpointIndependent Data Monitoring Committee agreed that the new targeted study size is appropriateEnrollment now expected to conclude in Q1 2023, with pivotal top-line data readout anticipated in Q3 2023 WARREN, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's proposal to reduce t
WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2022. "The Bellerophon team continues to advance our late-stage INOpulse® inhaled nitric oxide therapy platform for the treatment of fibrotic interstitial lung disease, or fILD, and pulmonary hypertension associated with sarcoidosis, or PH-Sarc," said Naseem Amin, M.D., Chairman of Bellerophon's Board of Directors. "Enrollment is steadily proceeding in o
WARREN, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2021. "We continue to progress our INOpulse® inhaled nitric oxide therapy in multiple areas of significant unmet need," said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. "Our ongoing pivotal Phase 3 REBUILD study for fibrotic interstitial lung disease, or fILD, patients at risk of associated pulmonary hypertension is progressing well and con
WARREN, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced the appointment of Naseem Amin, M.D., as Chairman of its Board of Directors, effective immediately. Dr. Amin, who has served as an Independent Director since 2015, will succeed Jonathan Peacock, who is retiring from the Company's Board. "It has been a privilege to work alongside the talented Bellerophon team over the past several years and to guide the Company's evolution into a late-stage development company," said Mr. Peacock. "With a number of
Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INO
SC 13G/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13G/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13G - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13D/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13D/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13G/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13D/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13G/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13G - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
SC 13D/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)
8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
DEFA14A - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
DEFA14A - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
DEFA14A - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
25-NSE - Bellerophon Therapeutics, Inc. (0001600132) (Subject)
8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)
8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)